That’s why we’re zeroing in on how to target the genetic mutations and mechanisms that facilitate this resistance process – including targeting multiple biological pathways simultaneously – with the potential to extend survival for patients with resistant cancers4.
However, many patients who initially respond to targeted therapies develop resistance to their treatment, causing it to stop working on cancer cells3 .That’s why we’re zeroing in on how to target the genetic mutations and mechanisms that facilitate this resistance process – including targeting multiple biological pathways simultaneously – with the potential to extend survival for patients with resistant cancers4.